Verve Therapeutics
Clinical trials sponsored by Verve Therapeutics, explained in plain language.
Now part of
Eli Lilly and Company
LLY
NYSE
Gene-editing biotech targeting cardiovascular disease.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Editing shot could slash cholesterol for good Results expected Oct 2026 (estimated)